ライフサイエンスコーパス: locally advanced

1 Vismodegib is approved for the treatment of locally advanced and metastatic basal cell carcinoma (BC

2 ns the principal treatment for patients with locally advanced and metastatic disease.

3 s and targeted therapy for the management of locally advanced and metastatic disease.

4 specific survival on univariate analysis for locally advanced and metastatic disease.

5 n combined with gemcitabine in patients with locally advanced and metastatic pancreatic cancer.

6 izumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urotheli

7 For patients with locally advanced and unresectable pancreatic cancer (PDA

8 2 and 3 clinical trials for the treatment of locally advanced and/or metastatic breast cancer with ge

9 outcomes for a broad group of patients with locally advanced and/or node-positive tumors, it is less

10 erall survival (OS) benefit in patients with locally advanced and/or positive regional lymph node dis

11 dynamic allocation, stratified by operable, locally advanced, and inflammatory breast cancer, and by

12 r treating patients who develop recurrent or locally advanced basal cell carcinoma (BCC), and will in

13 he Smoothened molecule and are indicated for locally advanced basal cell carcinoma (laBCC) and metast

14 cutoff (Nov 6, 2013), 499 patients (468 with locally advanced basal cell carcinoma and 31 with metast

15 central review, were noted among the 42 with locally advanced basal cell carcinoma and two (15%, 2-45

16 amous cell carcinoma within the tumor bed of locally advanced basal cell carcinoma found during vismo

17 302 (66.7%, 62.1-71.0) of 453 patients with locally advanced basal cell carcinoma had an overall res

18 Patients with locally advanced basal cell carcinoma had to have been d

19 Eligible patients had locally advanced basal cell carcinoma not amenable to cu

20 adult patients with histologically confirmed locally advanced basal cell carcinoma or metastatic basa

21 The first case is that of a patient with locally advanced basal cell carcinoma responsive to vism

22 hat of a patient with Gorlin syndrome with a locally advanced basal cell carcinoma that was stable wh

23 hway inhibitor vismodegib for metastatic and locally advanced basal cell carcinoma.

24 ghlight the importance of repeated biopsy in locally advanced basal cell carcinomas in 2 clinical sit

25 Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also appro

26 y is feasible for patients with recurrent or locally advanced BCC and that combined use of currently

27 Among the patients with locally advanced BCC, 5 had T3bN0M0 disease at presentat

28 Ten patients had locally advanced BCC; 2 had basal cell nevus syndrome.

29 years or older with borderline resectable or locally advanced biopsy-proven pancreatic ductal adenoca

30 All 7 patients had locally advanced, biopsy-proven, infiltrative BCC that w

31 se of adjuvant chemotherapy in patients with locally advanced bladder cancer postcystectomy who did n

32 ated with improved survival in patients with locally advanced bladder cancer.

33 Treatment of patients with locally advanced/borderline resectable (LA/BR) pancreati

34 Improvements in the treatment of locally advanced breast cancer (LABC) are needed.

35 Cs isolated from patients with metastatic or locally advanced breast cancer express high levels of th

36 Patients with HER2-positive locally advanced breast cancer or MBC were treated with

37 The LABC (locally advanced breast cancer) group included 17 patien

38 PET/CT in initial staging of inflammatory or locally advanced breast cancer?

39 Hypoxia is a common feature of locally advanced breast cancers that is associated with

40 All locally advanced breast cancers were (18)F-fluciclovine-

41 ontext of radioembolization in patients with locally advanced, but nonmetastatic, HCC and initially e

42 e exists whether in the type of resection in locally advanced cancer plays a role in prognosis and wh

43 The study comprised 52 patients with locally advanced carcinoma, treated first with combined

44 umab was recently approved for metastatic or locally advanced carcinomas arising in the stomach or in

45 ar PFS, 5-year OS, and pelvic recurrence for locally advanced cervical cancer clinically limited to t

46 o predict treatment failure in patients with locally advanced cervical cancer treated with chemo- and

47 Patients with locally advanced cervix cancer were randomly assigned to

48 tandard cisplatin (CIS) chemoradiotherapy in locally advanced cervix cancer.

49 and efficacy of multivisceral resection for locally advanced clinical T4b gastric cancer were assess

50 ckade may be a viable therapeutic option for locally advanced cSCC and provides rationale for further

51 A single patient with locally advanced cSCC who declined surgery and radiother

52 In 1 patient with locally advanced cSCC who was treated with pembrolizumab

53 d cell death 1 receptor (PD-1) inhibitors in locally advanced cSCC.

54 treatment, according to their perception as locally advanced (cT3) or early-stage tumors (stage II).

55 Patients and Methods Patients with locally advanced (cT3-4 or cN+) rectal cancer who were t

56 es are available in patients with inoperable locally advanced cutaneous squamous cell carcinoma (cSCC

57 entified 11 trials of docetaxel for men with locally advanced disease (M0).

58 Patients with locally advanced disease (T3/T4) presented with more sym

59 s population (patients with fully assessable locally advanced disease and all those with metastatic d

60 nts with pancreatic cancer have unresectable locally advanced disease at diagnosis.

61 , 35 (38%, 95% CI 28-48) of 93 patients with locally advanced disease had an objective response, as a

62 Locally advanced disease is generally managed with esoph

63 or older with dt-GCT of the soft tissue with locally advanced disease or resectable tumours requiring

64 disease, whereas patients with patients with locally advanced disease receive perioperative chemother

65 with metastases and 11 patients [6.0%] with locally advanced disease) at the National Institutes of

66 207 (25%) patients had inflammatory or locally advanced disease, 169 (20%) patients had tumours

67 11 studies, comprising 315 patients with locally advanced disease, reported survival outcomes and

68 With locally advanced disease, SNP rs1124736 (IGF1R) was asso

69 For patients with locally advanced disease, the focus is on limiting local

70 rioperative and postoperative strategies for locally advanced disease, which include chemotherapy and

71 umab-based therapy, which includes many with locally advanced disease.

72 r patients is increasing beyond the scope of locally advanced disease.

73 esophagectomy is indicated for patients with locally advanced disease.

74 rrence after treatment remain significant in locally advanced disease.

75 on and weight loss have predictive value for locally advanced disease.

76 eived neoadjuvant chemotherapy for localized/locally advanced disease; 51 received chemotherapy for u

77 se, we reviewed 97 consecutive patients with locally advanced EC and a pretreatment (18)F-FDG PET/CT

78 se, we reviewed 97 consecutive patients with locally advanced EC and a pretreatment (18)F-FDG PET/CT

79 step in predicting tumor response to nCRT in locally advanced EC.

80 a were patients undergoing esophagectomy for locally advanced esophageal adenocarcinoma post-neoadjuv

81 e accepted standard of chemoradiotherapy for locally advanced esophageal and gastroesophageal junctio

82 Operable patients with locally advanced esophageal cancer (clinically staged T3

83 Although often investigated in locally advanced esophageal cancer (EC), the impact of n

84 f sarcopenia in the multimodal management of locally advanced esophageal cancer (LAEC), and to assess

85 icting complete pathologic response (pCR) in locally advanced esophageal cancer (LAEC).

86 onse and long-term survival in patients with locally advanced esophageal cancer undergoing neoadjuvan

87 improved overall survival for patients with locally advanced esophageal cancer, and to evaluate how

88 apy is increasingly the standard of care for locally advanced esophageal cancer.

89 ence treatment and outcomes of patients with locally advanced esophageal cancer.

90 r OS and DM but not for LRC in patients with locally advanced esophageal carcinoma treated with defin

91 overall progress in the therapy of local and locally advanced esophageal, gastroesophageal junction,

92 to identify those postmenopausal women with locally advanced, estrogen-receptor-positive breast canc

93 In the West, the staging evaluations of locally advanced gastric cancer are not uniform.

94 f multivisceral resection, in the setting of locally advanced gastric cancer, is still debated.

95 ) of imatinib in patients with metastatic or locally advanced GI stromal tumors (GISTs).

96 cohort study of patients with metastatic or locally advanced grade 1-2 carcinoid tumours or pancreat

97 ive HCC was similar to that of patients with locally advanced HCC (stage IVA), which supports the val

98 ep3B-hCG orthotopic human xenograft model of locally advanced HCC.

99 adiotherapy (CRT) for patients with resected locally advanced head and neck cancer (LAHNC) with negat

100 FX-C) versus standard fractionation (SFX) in locally advanced head and neck carcinoma (LA-HNC).

101 nce every 3 weeks is the standard of care in locally advanced head and neck squamous cell cancer (LAH

102 apy, a standard of care for the treatment of locally advanced head and neck squamous cell cancers.

103 of response to radiotherapy and cetuximab in locally advanced head and neck squamous cell carcinoma (

104 ent response to radical chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (

105 ction chemotherapy (ICT) in the treatment of locally advanced head and neck squamous cell carcinoma r

106 to (90)Y radioembolization in patients with locally advanced hepatocellular carcinoma (HCC).

107 underwent left nephroureterectomy, revealing locally advanced high-grade UC invading the renal parenc

108 erience substantially influences survival in locally advanced HNC.

109 cisplatin and radiotherapy in patients with locally advanced HNSCC but failed to significantly incre

110 Single patient with locally advanced HNSCC who received erlotinib monotherap

111 ss the evidence for the current treatment of locally advanced human papillomavirus-negative HNSCC, as

112 Twenty-seven women with a new diagnosis of locally advanced IDC (n = 19) or ILC (n = 8) underwent P

113 medical clinics, treatment-naive adults with locally advanced, inflammatory, or early-stage HER2-posi

114 2) early-stage cancer after surgery, and (3) locally advanced inoperable cancer.

115 Women who have large or locally advanced invasive breast cancer (tumor size T3/T

116 Women who have large or locally advanced invasive breast cancer (tumor size T3/T

117 s: Twenty-four women with a new diagnosis of locally advanced invasive ductal breast cancer (n = 18)

118 Twenty-four women with a new diagnosis of locally advanced invasive ductal breast cancer (n = 18)

119 The management of locally advanced larynx cancer is challenging and requir

120 recommendations for staging in patients with locally advanced lung cancer in a national cohort.

121 The discovery of a locally advanced medullary thyroid cancer that is not am

122 e effectiveness of regional chemotherapy for locally advanced melanoma.

123 It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cance

124 ausal women with estrogen receptor-positive, locally advanced/metastatic breast cancer who had no pre

125 sparing treatment paradigm for patients with locally advanced MPM.

126 annually worldwide present with localised or locally advanced non-metastatic disease.

127 oxic effects in the definitive management of locally advanced non-small cell lung cancer (NSCLC), but

128 patients treated with chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLC).

129 ilure rates after radiation therapy (RT) for locally advanced non-small-cell lung cancer (NSCLC) rema

130 therapy (IMRT) is increasingly used to treat locally advanced non-small-cell lung cancer (NSCLC), IMR

131 external-beam radiotherapy for patients with locally advanced non-small-cell lung cancer (NSCLC).

132 nt FDG-PET to improve local tumor control of locally advanced non-small-cell lung cancer (NSCLC).

133 modality treatment of patients with operable locally advanced non-small-cell lung cancer.

134 apy (CIRT) holds promise to treat inoperable locally-advanced non-small cell lung carcinoma (NSCLC),

135 py is the standard treatment for inoperable, locally advanced, non-metastatic pancreatic cancer.

136 Eligible patients had locally advanced NSCLC and no contraindication to concom

137 d patients with metastatic, unresectable, or locally advanced NSCLC from 121 sites in Canada and the

138 study compares 3D-CRT and IMRT outcomes for locally advanced NSCLC in a large prospective clinical t

139 ng feature that may have prognostic value in locally advanced NSCLC patients with large tumors who ar

140 diac events exceeded 10% among patients with locally advanced NSCLC treated with definitive radiation

141 Patients with locally advanced NSCLC underwent (18)F-FDG PET prior to

142 Twenty-two patients with locally advanced NSCLC underwent surgery after induction

143 For curative-intent treatment of locally advanced NSCLC, concurrent chemoradiotherapy imp

144 ation or chemoradiotherapy in the setting of locally advanced NSCLC, phase II and III studies targete

145 viable tumor after induction chemotherapy in locally advanced NSCLC.

146 0617, which supports routine use of IMRT for locally advanced NSCLC.

147 upplemented surgery as standard treatment of locally advanced oesophageal cancer.

148 Total pancreatectomy may be required in locally advanced or centrally located pancreatic neoplas

149 uvant concurrent chemoradiotherapy (CRT) for locally advanced or incompletely resected non-small-cell

150 wed by adjuvant trastuzumab in patients with locally advanced or inflammatory breast cancer, and prov

151 tin (NOAH) trial in women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuv

152 randomised trial in women with HER2-positive locally advanced or inflammatory breast cancer.

153 confirmed EGFR Thr790Met-positive mutations, locally advanced or metastatic (stage IIIB/IV) NSCLC who

154 adult patients with histologically confirmed locally advanced or metastatic adrenocortical carcinoma

155 has been reported to be effective for select locally advanced or metastatic basal cell carcinomas.

156 ients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-positi

157 eribulin with capecitabine in patients with locally advanced or metastatic breast cancer (MBC).

158 or progesterone receptor-positive, or both, locally advanced or metastatic breast cancer from 113 ac

159 rs or older with HER2-positive unresectable, locally advanced or metastatic breast cancer previously

160 for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have no

161 mal growth factor (HER2)-negative inoperable locally advanced or metastatic breast cancer whose disea

162 ed hormone-receptor-positive, HER2-negative, locally advanced or metastatic breast cancer, who had re

163 andard of care for hormone receptor-positive locally advanced or metastatic breast cancer.

164 e aged 18 years or older with ALK-rearranged locally advanced or metastatic cancer that had progresse

165 ctively collected data from 51 patients with locally advanced or metastatic cancer undergoing treatme

166 t patients (aged >/=18 years) diagnosed with locally advanced or metastatic carcinoma of the pancreas

167 Patients and Methods Eligible patients had locally advanced or metastatic ccRCC that had progressed

168 with radioactive iodine ((131)I)-refractory locally advanced or metastatic differentiated thyroid ca

169 patients with radioactive iodine-refractory locally advanced or metastatic differentiated thyroid ca

170 asal cell carcinoma, therapeutic options for locally advanced or metastatic disease are limited.

171 ans were obtained in 21 patients with either locally advanced or metastatic disease.

172 hs worldwide, and most patients present with locally advanced or metastatic disease.

173 use of an NSAI as adjuvant treatment or for locally advanced or metastatic disease.

174 s currently in clinical trials in women with locally advanced or metastatic estrogen receptor-positiv

175 Patients with locally advanced or metastatic gastric or EGJ cancer wer

176 adults (aged >/=18 years) with unresectable locally advanced or metastatic gastric or gastro-oesopha

177 patients (>/=18 years old) with unresectable locally advanced or metastatic gastric or oesophagogastr

178 n 23 countries, we enrolled patients who had locally advanced or metastatic non-small-cell lung cance

179 tients aged 18 years or older with confirmed locally advanced or metastatic NSCLC.

180 cant clinical response in most patients with locally advanced or metastatic orbital or periocular BCC

181 We reviewed all patients with locally advanced or metastatic orbital or periocular BCC

182 H-302 in patients with previously untreated, locally advanced or metastatic pancreatic cancer.

183 mbination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer.

184 atment naive, aged older than 18 years, with locally advanced or metastatic pancreatic ductal adenoca

185 thods Patients with histologically confirmed locally advanced or metastatic PRCC were enrolled and re

186 domised, phase 2 trial, we enrolled men with locally advanced or metastatic prostate cancer scheduled

187 It recruits men with high-risk, locally advanced or metastatic prostate cancer who were

188 Among men with locally advanced or metastatic prostate cancer, ADT plus

189 For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has b

190 had a histologically confirmed diagnosis of locally advanced or metastatic soft-tissue sarcoma not p

191 igible patients had histologically confirmed locally advanced or metastatic soft-tissue sarcoma of Tr

192 ents when selecting first-line treatment for locally advanced or metastatic soft-tissue sarcoma.

193 years or older with measurable, inoperable, locally advanced or metastatic triple-negative breast ca

194 recruited previously untreated patients with locally advanced or metastatic urothelial cancer who wer

195 ally or cytologically confirmed diagnosis of locally advanced or metastatic urothelial cancer, includ

196 PD-1 antibody pembrolizumab in patients with locally advanced or metastatic urothelial cancer.

197 Few options exist for patients with locally advanced or metastatic urothelial carcinoma afte

198 erapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is a

199 nd point for prolonging PFS in patients with locally advanced or metastatic urothelial carcinoma rece

200 th histologically or cytologically confirmed locally advanced or metastatic urothelial carcinoma that

201 ity and safety of nivolumab in patients with locally advanced or metastatic urothelial carcinoma whos

202 patients (aged >/=18 years) with inoperable locally advanced or metastatic urothelial carcinoma whos

203 profile in previously treated patients with locally advanced or metastatic urothelial carcinoma.

204 of platinum-based regimens for patients with locally advanced or metastatic urothelial carcinoma.

205 expanded treatment options for patients with locally advanced or metastatic urothelial carcinoma.

206 Older men with locally advanced or screen-detected high-risk prostate c

207 For most sarcomas, locally advanced or unresectable disease is still treate

208 aive, histologically confirmed metastatic or locally advanced (or both) clear-cell renal cell carcino

209 ious chemotherapy regimens for unresectable, locally advanced, or metastatic disease (0 or 1 vs >1),

210 itive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric cancer, includin

211 CAD for the treatment of men with relapsing, locally advanced, or metastatic prostate cancer who achi

212 y-based image-guided (IGRT) radiotherapy for locally advanced oropharyngeal cancer.

213 nts undergoing concurrent chemoradiation for locally advanced oropharyngeal cancers was conducted.

214 trial performed to date among patients with locally advanced pancreatic cancer (LAPC) and the first

215 en increasingly utilized in the treatment of locally advanced pancreatic cancer (LAPC).

216 2015, 25 patients with histologically proved locally advanced pancreatic cancer 5 cm or smaller (13 w

217 neous irreversible electroporation (IRE) for locally advanced pancreatic cancer and (b) evaluate the

218 treatment option for some GI tumors such as locally advanced pancreatic cancer and primary or metast

219 Conclusion Percutaneous IRE for locally advanced pancreatic cancer is generally well tol

220 atients who underwent surgical resection for locally advanced pancreatic cancer ranged from 0% to 43%

221 Patients with locally advanced pancreatic cancer treated with FOLFIRIN

222 Consecutive patients with cephalic locally advanced pancreatic cancer who underwent surgica

223 el, randomized trial involving patients with locally advanced pancreatic cancer with disease controll

224 In locally advanced pancreatic cancer, the role of chemorad

225 ceived FOLFIRINOX as first-line treatment of locally advanced pancreatic cancer.

226 irinotecan and oxaliplatin) in patients with locally advanced pancreatic cancer.

227 lying a biologic basis for presentation with locally advanced pancreatic cancer.

228 s and outcome in patients with localized and locally advanced pancreatic cancer.

229 ter induction chemotherapy for patients with locally advanced pancreatic cancer.

230 689 patients, of whom 355 (52%) patients had locally advanced pancreatic cancer.

231 l therapies in highly selected patients with locally advanced PC, following a prolonged period of ind

232 noma (PDAC), making it a rational choice for locally advanced PDAC (LA).

233 Group performance status 0-1, metastatic or locally advanced previously treated solid tumours, and a

234 c exenteration was compared in patients with locally advanced primary (LAP) cancer and recurrent rect

235 ions that include cancer stem-like cells, in locally advanced primary and metastatic TNBC.

236 Patients undergoing major rectal surgery for locally advanced primary or recurrent rectal carcinoma (

237 plus RT) relative to ADT alone for men with locally advanced prostate cancer reported in two randomi

238 The addition of RT to ADT for patients with locally advanced prostate cancer significantly improved

239 on treatment is a viable option for treating locally advanced prostate cancer.

240 the role of RT in the treatment of men with locally advanced prostate cancer.

241 randomized controlled trial of patients with locally advanced prostate cancer.

242 ADT with radiotherapy (RT) for patients with locally advanced prostate cancer.

243 therapy (ADT) improves survival in men with locally advanced prostate cancer.

244 hort, which included men age > 75 years with locally advanced prostate cancer; and (3) the screen-det

245 In the PRT setting of locally advanced RC, SRCC patients had significantly wor

246 abase identified patients with nonmetastatic locally advanced rectal adenocarcinoma from 2010 to 2014

247 Patients with locally advanced rectal adenocarcinoma were treated with

248 in subgroups of patients with nonmetastatic locally advanced rectal cancer (LARC).

249 l study groups of patients with stage II-III locally advanced rectal cancer at 17 institutions in the

250 e neoadjuvant chemotherapy and radiation for locally advanced rectal cancer complete postoperative ad

251 The success of neoadjuvant CRT for locally advanced rectal cancer has changed an already co

252 The standard of care in locally advanced rectal cancer is preoperative, long cou

253 mor volume (WTV) methods in 62 patients with locally advanced rectal cancer on pre- and post-CRT imag

254 In the United Kingdom, patients with locally advanced rectal cancer routinely receive neoadju

255 ng patients who received neoadjuvant CRT for locally advanced rectal cancer were acquired.

256 , T2-weighted, and DWI) of 140 patients with locally advanced rectal cancer were included in our anal

257 Patients with locally advanced rectal cancer who achieve a pathologica

258 py followed by total mesorectal excision for locally advanced rectal cancer, patients who experience

259 l excision (TME) is the standard of care for locally advanced rectal cancer.

260 tment responders during preoperative CRT for locally advanced rectal cancer.

261 fter preoperative chemoradiotherapy (CRT) in locally advanced rectal cancer.

262 ted with a survival benefit in patients with locally advanced rectal cancer.

263 are needed to improve chemoradiotherapy for locally advanced rectal cancer.

264 rd chemoradiation is needed in patients with locally advanced rectal cancer.

265 of elderly patients (70 years or older) with locally advanced rectal cancers to image-guided radiothe

266 ffect of preoperative radiotherapy (PRT) for locally advanced rectal SRCC in a large patient group fr

267 nd were newly diagnosed with stage II to III locally advanced, resectable adenocarcinoma of the rectu

268 nce of metastatic or surgically unresectable locally advanced sarcoma, had received up to three previ

269 Patients with locally advanced SCCHN were randomly assigned to receive

270 ommended routinely in patients with N2 or N3 locally advanced SCCHN.

271 In the locally advanced setting, perioperative chemotherapy or

272 t cetuximab (CTX) as first-line treatment of locally advanced squamous cell carcinoma of the head and

273 therapy lowers distant failure (DF) rates in locally advanced squamous cell carcinoma of the head and

274 iated with overall survival in patients with locally advanced squamous cell carcinoma of the head and

275 etrospective study included 72 patients with locally advanced squamous cell carcinoma of the head and

276 py is a standard treatment for patients with locally advanced squamous cell carcinoma of the head and

277 able (>/= 10 mm for at least one dimension), locally advanced squamous-cell carcinoma of the head and

278 In patients with locally advanced squamous-cell carcinoma of the head and

279 emoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and

280 d, phase 2 trial, we recruited patients with locally advanced squamous-cell carcinoma of the head and

281 and neck, and the role of EGFR inhibition in locally advanced squamous-cell carcinoma of the head and

282 able (>/= 10 mm for at least one dimension), locally advanced squamous-cell carcinoma of the head and

283 iotherapy alone in patients with unresected, locally advanced squamous-cell carcinoma of the head and

284 d, phase 2 trial, we recruited patients with locally advanced squamous-cell carcinoma of the head and

285 s require some form of palliation because of locally advanced stage or distant metastasis, where it c

286 categorized as localized (stages I and II), locally advanced (stages III and IVB), or metastatic (st

287 For patients with locally advanced (T3, T4) disease, organ-preservation su

288 tient-derived xenograft (PDX) engraftment in locally advanced tumors (T3-T4 or N+) predict poor progn

289 Notably, MCAM and LAMA4 were enhanced in locally advanced tumors as well as both the primary tumo

290 Locally advanced tumors had no evidence of metastatic di

291 ssible impact of neoadjuvant pretreatment in locally advanced tumors should be considered with cautio

292 It had a higher yield in locally advanced tumors than in early-stage tumors; howe

293 ), nonlocoregional lymph nodes (n = 47), and locally advanced unresectable disease (n = 18), that is,

294 ficacy of radiation therapy in patients with locally advanced unresectable PDA have reported mixed re

295 ed in randomized controlled trials involving locally advanced, unresectable pancreatic cancer.

296 We included patients with locally advanced, unresectable, or metastatic high-grade

297 2013, 140 patients with previously untreated locally advanced, unresectable, or metastatic soft-tissu

298 ith single-drug doxorubicin in patients with locally advanced, unresectable, or metastatic soft-tissu

299 ent of disease: resected for cure (n = 400), locally advanced/unresected (n = 443), and metastatic (n

300 r with metastatic or surgically unresectable locally advanced urothelial carcinoma, measurable diseas